https://www.cancernetwork.com/view/nccn-guidelines-recommend-taletrectinib-for-ros1-nsclc-subtype
NCCN Guidelines Recommend Taletrectinib for ROS1+ NSCLC Subtype | CancerNetwork
May 15, 2026 - Previous data presented at the 2026 AACR Annual Meeting demonstrate the efficacy of taletrectinib in ROS1-positive NSCLC harboring brain metastases.
nccn guidelinesrecommendnsclc
https://www.nccn.org/education-research/continuing-education-(ce)/nccn-guidelines-in-practice/about-the-nccn-guidelines-in-practice
About the NCCN Guidelines in Practice™
Earn CME/CE/MOC credit with NCCN Guidelines in Practice™ by using NCCN Guidelines to support real-time clinical decisions in oncology care.
about thenccn guidelines